Bacteria and irritable bowel syndrome: The evidence for small intestinal bacterial overgrowth

Current Gastroenterology Reports

Volumn 8, Issue 4, 2006, Pages 305-311

  Lee, Hyo Rang ^b   Pimentel, Mark ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; DOXYCYCLINE; ERYTHROMYCIN; METHANE; NEOMYCIN; RIFAXIMIN; TEGASEROD;

BACTERIAL OVERGROWTH; BREATH ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE DURATION; DRUG ABSORPTION; EVIDENCE BASED MEDICINE; GASTROENTERITIS; HUMAN; INTESTINE FLORA; INTESTINE TRANSIT TIME; IRRITABLE COLON; PATHOPHYSIOLOGY; REVIEW; SMALL INTESTINE DISEASE;

BACTERIA; HUMANS; INTESTINE, SMALL; IRRITABLE BOWEL SYNDROME;

EID: 33746885430     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-006-0051-3     Document Type: Review

References (65)

1. Drossman DA, Sandler RS, McKee DL, et al.: Bowel patterns among subjects not seeking health care. Gastroenterology 1982, 83:529-534.
2. Thompson WG, Heaton KW: Functional bowel disorders in apparently healthy people. Gastroenterology 1980, 79:283-288.
3. Thompson WG: The functional gastrointestinal bowel disorders. In The Functional Gastrointestinal Disorders. Edited by Drossman DA. Boston: Little, Brown; 1994:117-134.
4. Drossman DA: Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med 1999, 107:41S-50S.
5. Ritchie J: Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973, 14:125-132.
6. Prior A, Maxton DG, Whorwell PJ: Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects. Gut 1990, 31:458-462.
7. Richter JE, Barish CF, Castell DO: Abnormal sensory perception in patients with esophageal chest pain. Gastroenterology 1986, 91:845-852.
8. Whitehead WE, Holtkotter B, Enck P, et al.: Tolerance for rectosigmoid distension in irritable bowel syndrome. Gastroenterology 1990, 98:1187-1192.
9. Bradette M, Pare P, Douville P, et al.: Visceral perception in health and functional dyspepsia. Crossover study of gastric distension with placebo and domperidone. Dig Dis Sci 1991, 36:52-58.
10. Lemann M, Dederding JP, Flourie B, et al.: Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. The irritable stomach syndrome. Dig Dis Sci 1991, 36:1249-1254.
11. Mearin F, Cucala M, Azpiroz F, et al.: The origin of symptoms on the brain-gut axis in functional dyspepsia. Gastroenterology 1991, 101:999-1006.
12. Mayer EA, Gebhart GF: Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994, 107:271-293.
13. Mertz H, Nabiloff B, Munakata J, et al.: Altered rectal perception is a biological marker of patients with the irritable bowel syndrome. Gastroenterology 1995, 109:40-52.
14. Nabiloff BD, Mayer EA: Sensational developments in irritable bowel syndrome. Gut 1996, 39:770-771.
15. Munakata J, Nabiloff B, Harraf F, et al.: Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997, 112:55-63.
16. Lembo T, Munakata J, Nabiloff B, et al.: Sigmoid afferent mechanisms in patients with irritable bowel syndrome. Dig Dis Sci 1997, 42:1112-1120.
17. Harraf F, Schmulson M, Saba L, et al.: Subtypes of constipation predominant irritable bowel syndrome based on rectal perception. Gut 1998, 43:388-394.
18. Whitehead WE, Palsson OS: Is rectal pain sensitivity a biological marker for irritable bowel syndrome: Psychological influences on pain perception. Gastoenterology 1998, 115:1263-1271.
19. Chun A, Desautels S, Slivka A, et al.: Visceral algesia in irritable bowel syndrome fibromyalgia, and sphincter of Oddi dysfuntion, type III. Dig Dis Sci 1999, 44:631-636.
20. O'Brien MD, Phillips SF: Colonic motility in health and disease. Gastroenterol Clin North Am 1996, 25:147-162.
21. McKee DP, Quigley FM: Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility. Dig Dis Sci 1993, 38:1761-1772.
22. McKee DP, Quigley FM: Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach, and gall-bladder. Dig Dis Sci 1993, 38:1773-1782.
23. Lind CD: Motility disorders in the irritable bowel syndrome. Gastroenterol Clin North Am 1991, 20:279-295.
24. Drossman DA, Li Z, Andruzzi E, et al.: U.S. householder study on functional gastrointestinal disorders Prevalence, sociodemography and health impact. Dig Dis Sci 1993, 38:1569-1580.
25. Halpert A, Dalton CB, Diamant NE, et al.: Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005 Mar, 100:664-671.
26. Tabas G, Beaves M, Wang J, et al.: Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004, 99:914-920.
27. Patrick DL, Drossman DA, Frederick IO, et al.: Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998, 43:400-411.
28. Talley NJ: Antidepressants in IBS: Are we deluding ourselves? Am J Gastroenterol 2004, 99:921-923.
29. Neal KR, Hebden J, Spiller R: Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis, and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997, 314:779-782.
30. Parry SD, Stansfield R, Jelley D, et al.: Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study. Am J Gastroenterol 2003, 98:238-241.
31. Neal KR, Barker L, Spiller RC: Prognosis in post-infectious irritable bowel syndrome: a six year follow up study. Gut 2002, 51:410-413.
32. Barber R, Blakey A: Prevalence of gastrointestinal symptoms after bacterial gastroenteritis: study did not include control group. BMJ 1997, 314:1903.
33. Spiller RC, Jenkins D, Thornley JP, et al.: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000, 47:804-811.
34. Dunlop SP, Jenkins D, Neal KR, et al.: Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003, 18:77-84.
35. O'Mahony L, McCarthy J, Kelly P, et al.: Lactobacillus and Bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 2005, 128:541-551.
36. Lewis MJ, Reilly B, Houghton LA, Whorwell PJ: Ambulatory abdominal inductance plethysmography: towards objective assessment of abdominal distension in irritable bowel syndrome. Gut. 2001, 48:216-220.
37. King TS, Elia M, Hunter JO: Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998, 352:1187-1189.
38. Koide A, Yamaguchi T, Odaka T, et al.: Quantitative analysis of bowel gas using plain abdominal radiograph in patients with irritable bowel syndrome. Am J Gastroenterol 2000, 95:1735-1741.
39. Salvioli B, Serra J, Azpiroz F, et al.: Origin of gas retention and symptoms in patients with bloating. Gastroenterology 2005, 128:574-579.
40. Pimentel M, Soffer EE, Chow EJ, et al.: Low frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 2002, 47:2639-2643.
41. Pimentel M, Chow EJ, Lin HC: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000, 95:3503-3506.
42. Pimentel M, Chow EJ, Lin HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: A double blind randomized, placebo controlled study. Am J Gastroenterol 2003, 98:412-419.
43. Galatola G, Grosso M, Barlotta A, et al.: Diagnosis of bacterial contamination of the small intestine using the 1 g [14C] xylose breath test in various gastrointestinal diseases. Minerva Gastroenterol Dietol 1991, 37:169-175.
44. Nucera G, Gabriella M, Lupascu A, et al.: Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005, 21:1391-1395.
45. Lupascu A, Gabrielli M, Lauritano EC, et al.: Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005, 22:1157-1160.
46. McCallum R, Schultz C, Sostarich S: Evaluating the role of small intestinal bacterial overgrowth (SIBO) in diarrhea predominant irritable bowel syndrome (IBS-D) patients utilizing the glucose breath test (GBT). Gastroenterol 2005, 128:A460.
47. Walters B, Vanner SJ: Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 2005, 100:1566-1570.
48. Simren M, Ringstorm G, Agerforz P, et al.: Small intestinal bacterial overgrowth is not of major importance in irritable bowel syndrome, Gastroenterology 2003, 124:A163.
49. Robson KM, Kakullavarapu J, Lembo T. Bacterial overgrowth and irritable bowel syndrome: a look at prevalence: symptoms and quality of life. Am J Gastroenterol 2003, 98:S271.
50. ROME II: The Functional Gastrointestinal Disorders, edn 2. McLean, VA: Management Services, Degnon Associates; 2006.
51. Pimentel M, Mayer AG, Park S, et al.: Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci 2003, 48:86-92.
52. Fiedorek SC, Pumphrey CL, Casteel HB: Breath methane production in children with constipation and encoparesis. J Pediatr Gastroenterol 1990, 10:473-477.
53. Fiedorek SC, Pumphrey CL, Casteel HB: Breath methane production in children with constipation and encoparesis. J Pediatr Gastroenterol 1990, 10:473-477.
54. Pimentel M, Lin HC, Enayati P, et al.: Methane, a gas produced by enteric bacteria, slows intestinal transit and augments ileal contractile activity. Am J Physiol S Gastrointest Liver Physiol 2006, 290:G1089-G1095.
55. Cloarec D, Bornet F, Gouilloud S, et al.: Breath hydrogen response to lactulose in healthy subjects: relationship to methane producing status. Gut 1990, 31:300-304.
56. Stephan AM, Wiggins HS, Englyst HN, et al.: The effect of age, sex and level of dietary fiber from wheat on large-bowel function in thirty healthy subjects. Br J Nutr 1986, 56:349-361.
57. Soares AC, Lederman HM, Fagundes-Neto U, et al.: Breath methane associated with slow colonic transit time in children with chronic constipation. J Clin Gastroenterol 2005, 39:512-515.
58. Vantrappen G, Janssens J, Hellemans J, Ghoos Y: The interdigestive Motor complex of normal subjects with bacterial overgrowth of the small intestine. J Clin Invest 1977, 59:1158-1166.
59. Szurszewski JH: A migrating electric complex of the canine small intestine. Am J Physiol 1969, 217:1757-1763.
60. Pimentel M, Soffer EE, Chow EJ, Lin HC: Lower frequency of MMC is found in IBS subjects with abnormal breath test suggesting bacterial overgrowth. Dig Dis Sci 2002, 47:2639-2643.
61. Bjornsson ES, Abrahamsson H: Comparison between physiologic and erythromycin-induced interdigestive motility. Scand J Gastroenterol 1995, 30:139-145.
62. Attar A, Fluorie B, Rambaud JC, et al.: Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999, 117:794-797.
63. Di Stefano M, Malservisi S, Veneto G, et al.: Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000, 14:551-556.
64. Sharara AI, Aoun E, Abdul-Baki H, et al.: A randomized double blind placebo controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006, 101:326-333.
65. Pimentel M, Park S, Kong Y, Kane SV: Rifaximin, a non-absorbable antibiotic improves the symptoms of irritable bowel syndrome: A double-blind randomized controlled study. Am J Gastroenterol 2005, 100:S324.